Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective post-marketing study of Berinert for hereditary angioedema (C1-INH deficiency) focusing on inhibitory antibody formation
2010-024242-30Phase 4Completed
- Sponsor
- CSL Limited
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by CSL Limited. Primary endpoint: Incidence of inhibitory anti-C1-INH antibodies. Started Aug 2011; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2010-024242-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024242-30.